Vistagen Therapeutics Inc · Q2 2025 earnings

Briefing

Reported financial results for the second quarter of fiscal year 2025 and provided a corporate update.

Vistagen reported a net loss of $13.0 million for the quarter ended September 30, 2024, compared to a net loss of $6.6 million for the same period in 2023. Research and development expenses increased to $10.2 million, and general and administrative expenses rose to $4.2 million. The company's cash, cash equivalents, and marketable securities totaled $97.6 million as of September 30, 2024.

• Initiated PALISADE-4 Phase 3 trial for fasedienol in Q2 2025.
• PALISADE-3 and PALISADE-4 Phase 3 trials remain on track to produce top-line results in 2025.
• Preparing for Phase 2B development of itruvone for major depressive disorder.
• Ongoing U.S. IND-enabling program for PH80 to facilitate further Phase 2 clinical development for hot flashes.

Headline financials

Revenue & EPS history

As we head into 2025, we expect data from multiple Phase 3 clinical trials in social anxiety disorder and further advancement of our non-systemic pherine product candidates in Phase 2 programs for treatment of major depressive disorder and hormone-free treatment of menopausal hot flashes, each with potential to set a new standard of care.